Page last updated: 2024-12-05

butorphanol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

Butorphanol: A synthetic morphinan analgesic with narcotic antagonist action. It is used in the management of severe pain. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

butorphanol : Levorphanol in which a hydrogen at position 14 of the morphinan skeleton is substituted by hydroxy and one of the hydrogens of the N-methyl group is substituted by cyclopropyl. A semi-synthetic opioid agonist-antagonist analgesic, it is used as its (S,S)-tartaric acid salt for relief or moderate to severe pain. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5361092
CHEMBL ID33986
CHEBI ID3242
SCHEMBL ID3749
MeSH IDM0003094

Synonyms (48)

Synonym
BIDD:GT0549
butorphanolum
levo-bc-2627
17-(cyclobutylmethyl)morphinan-3,14-diol
D03197
butorphanol (usan/inn)
morphinan-3,14-diol, 17-(cyclobutylmethyl)-
butorfanol
butorfanol [inn-spanish]
butorphanolum [inn-latin]
dea no. 9720
l-bc 2627
einecs 255-808-8
butorphanol
42408-82-2
C06863
(-)-n-cyclobutylmethyl-3,14-dihydroxymorphinan
(-)-butorphanol
(-)-17-(cyclobutylmethyl)morphinan-3,14-diol
bdbm50240437
chebi:3242 ,
CHEMBL33986 ,
butorphanol [usan:inn:ban]
qv897jc36d ,
unii-qv897jc36d
butorphanol [usan]
butorphanol [who-dd]
butorphanol [inn]
butorphanol [vandf]
butorphanol [mi]
gtpl7591
SCHEMBL3749
n-cyclobutylmethyl-3,14-dihydroxymorphinan
J-504151
Q-200770
l-n-cyclobutylmethyl-3,14-dihydroxymorphinan
DTXSID1022714 ,
(1s,9r,10s)-17-(cyclobutylmethyl)-17-azatetracyclo[7.5.3.0^{1,10}.0^{2,7}]heptadeca-2(7),3,5-triene-4,10-diol
Q1185089
(1s,9r,10s)-17-(cyclobutylmethyl)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-triene-4,10-diol
butorphanol (free base)
42408-82-2 (free base)
(4bs,8as,9r)-11-(cyclobutylmethyl)-5,6,7,8,9,10-hexahydro-8ah-9,4b-(epiminoethano)phenanthrene-3,8a-diol
butorfanol (inn-spanish)
dtxcid502714
butorphanolum (inn-latin)
n02af01
butorfanolo

Research Excerpts

Toxicity

meloxicam is a safe and effective method of controlling postoperative pain for 20 hours in dogs undergoing abdominal surgery. Butorphanol is considered an effective and safe analgesic after cesarean delivery but is associated with profound dose-dependent sedation.

ExcerptReferenceRelevance
" Adverse cardiovascular and respiratory depressant effects were not observed."( Dose effectiveness and safety of butorphanol in acute migraine headache.
Elenbaas, RM; Evens, RP; Gratton, M; Iacono, CU; Koellner, KJ; Pribble, JP; Racz, G, 1991
)
0.28
" Adverse effects, such as dizziness, nausea, thirst, numbness of the hands etc, observed in 5 patients were transient and required no medication."( [Clinical trial of butorphanol tartrate in cancer patients: evaluation for analgesic effects and safety on the basis of long term administration].
Ebina, A; Hayashi, I; Ito, T; Konno, K; Nagai, K; Nakai, Y; Sato, M, 1983
)
0.27
"Anesthesia in the white rhinoceros (Ceratotherium simum) has routinely involved potent narcotic anesthetic agents such as etorphine or carfentanil with their associated adverse side effects."( Butorphanol and azaperone as a safe alternative for repeated chemical restraint in captive white rhinoceros (Ceratotherium simum).
Childs, SE; Ferrell, ST; Radcliffe, RW, 2000
)
0.31
"Results suggest that preoperative administration of meloxicam is a safe and effective method of controlling postoperative pain for 20 hours in dogs undergoing abdominal surgery; the analgesic effects of meloxicam were comparable to those of ketoprofen and superior to those of butorphanol."( Safety and efficacy of preoperative administration of meloxicam, compared with that of ketoprofen and butorphanol in dogs undergoing abdominal surgery.
Foster, R; Mathews, KA; McDonell, W; Pettifer, G, 2001
)
0.31
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
" Heart and respiratory rate, and procedure and recovery times were similar for all treatment groups, and no adverse events were observed during the study."( Clinical efficacy and safety of dexmedetomidine and buprenorphine, butorphanol or diazepam for canine hip radiography.
Granholm, MM; Leppänen, MK; McKusick, BC; Short, CE; Tulamo, R; Westerholm, FC, 2006
)
0.33
"Butorphanol is considered an effective and safe analgesic after cesarean delivery but is associated with profound dose-dependent sedation."( The efficacy and safety of low dose epidural butorphanol on postoperative analgesia following cesarean delivery.
Basnet, N; Bhattarai, B; Khaniya, S; Pokharel, K; Rahman, TR; Singh, SN,
)
0.13
" Any adverse clinical effects such as somnolence, dizziness, nausea or vomiting were recorded."( Efficacy and safety of transnasal butorphanol for pain relief after anal surgery.
Chou, YC; Hsiao, CW; Jao, SW; Mai, CM; Wan, LT; Wu, CC; Yang, HY, 2009
)
0.35
" Length of hospital stay and the incidence of adverse effects between the groups were similar."( Efficacy and safety of transnasal butorphanol for pain relief after anal surgery.
Chou, YC; Hsiao, CW; Jao, SW; Mai, CM; Wan, LT; Wu, CC; Yang, HY, 2009
)
0.35
"Pruritus is a frequent adverse event after administration of morphine."( Butorphanol prevents morphine-induced pruritus without increasing pain and other side effects: a systematic review of randomized controlled trials.
Du, BX; Shi, XY; Song, ZM; Wang, K; Xu, FY; Zhang, H; Zou, Z, 2013
)
0.39
"Analyses were performed to investigate relationships between dose administered, age, individual reactions, adverse effects and changes in dive physiology."( Using a combination of midazolam and butorphanol is a safe and effective reversible field sedation protocol for Weddell seal (Leptonychotes weddellii) pups.
Brodie, E; Harris, HS; Johnson, S; Liwanag, HEM; Pearson, LE; Whitmer, ER; Whoriskey, S, 2022
)
0.72
"2 mg/kg) provided safe and effective sedation, with reversible effects, in Weddell seal pups."( Using a combination of midazolam and butorphanol is a safe and effective reversible field sedation protocol for Weddell seal (Leptonychotes weddellii) pups.
Brodie, E; Harris, HS; Johnson, S; Liwanag, HEM; Pearson, LE; Whitmer, ER; Whoriskey, S, 2022
)
0.72
"The combination of intranasal midazolam-butorphanol and intramuscular alfaxalone at the doses examined was a safe and effective method for sedating Quaker parrots."( Intranasal butorphanol and midazolam administered prior to intramuscular alfaxalone provides safe and effective sedation in Quaker parrots (Myiopsitta monachus).
Conner, CM; Hoppes, SM; Simon, BT; Stevens, BJ, 2022
)
0.72

Pharmacokinetics

There were no statistically significant differences in the pharmacokinetic parameters, Cmax, tmax, AUC, and t1/2, for butorphanol with or without metoclopramide. For subcutaneous injection, absorption half-life and peak plasma concentration ofbutorphanol were 0.

ExcerptReferenceRelevance
"145 (mean +/- SD) 1/kg, mean elimination half-life was 82 min, and clearance was 34."( Pharmacokinetics and milk residues of butorphanol in dairy cows after single intravenous administration.
Court, MH; Dodman, NH; Hustead, DR; Lee, JW; Levine, HD; Richey, MT, 1992
)
0.28
"The pharmacokinetic properties of butorphanol tartrate were determined in 7 rabbits after IV and SC injection (0."( Pharmacokinetics of butorphanol tartrate in rabbits.
Hustead, DR; Portnoy, LG, 1992
)
0.28
"40 liters/kg), distribution half-life (7."( Influence of age on the pharmacokinetics of butorphanol.
Higbee, M; Maesner, J; Ramsey, R; Wood, J, 1988
)
0.27
" There were no statistically significant differences for butorphanol between the 2 treatments on any of the following pharmacokinetic parameters: Cmax, tmax, AUC, t1/2, CL/f, and Vz/f."( Lack of pharmacokinetic interaction between butorphanol tartrate nasal spray and sumatriptan succinate.
Barbhaiya, RH; Lee, JS; Shyu, WC; Srinivas, NR; Upmalis, D, 1995
)
0.29
" Dose-dependent differences in pharmacokinetic regularities of sodium thiopental in the groups compared have been revealed."( [Pharmacokinetics and pharmacodynamics of thiopental sodium in pregnant women during cesarean section].
Folomeeva, IIu; Proshina, IV; Sariev, AK; Zerdev, VP,
)
0.13
" However, there were no significant differences in Cmax and AUC between the groups after transnasal administration."( The effects of age and sex on the systemic availability and pharmacokinetics of transnasal butorphanol.
Barbhaiya, RH; Morgenthien, EA; Pittman, KA; Shyu, WC, 1994
)
0.29
"Pharmacokinetic and pharmacodynamic monitoring of moradol (2 mg) given to 16 somatically healthy parturients during analgesia of spontaneous labor has identified 2 groups of patients who significantly differed in kinetic characteristics and in the drug's ability to penetrate through the placenta barrier."( [The pharmacokinetic and pharmacodynamic characteristics of moradol in parturients during obstetrical analgesia].
Kozhakhmetov, AN; Proshina, IV; Sariev, AK; Zherdev, VP,
)
0.13
" However, total plasma clearance (CL), steady-state volume of distribution, area under the concentration-time curve [AUC(0-infinity)], and elimination half-life of butorphanol in patients with hepatic impairment were significantly altered (approximately twofold to threefold)."( The absolute bioavailability and pharmacokinetics of butorphanol nasal spray in patients with hepatic impairment.
Barbhaiya, RH; Garnett, WR; Morgenthien, EA; Shyu, WC; Vachharajani, NN, 1996
)
0.29
"Based on the comparable Cmax but the increased AUC in patients with liver dysfunction, the initial dose of butorphanol nasal spray may not need to be adjusted."( The absolute bioavailability and pharmacokinetics of butorphanol nasal spray in patients with hepatic impairment.
Barbhaiya, RH; Garnett, WR; Morgenthien, EA; Shyu, WC; Vachharajani, NN, 1996
)
0.29
"The potential for a pharmacokinetic interaction between butorphanol nasal spray and cimetidine, under steady state conditions, was evaluated in 16 healthy male volunteers."( Lack of pharmacokinetic interaction between butorphanol nasal spray and cimetidine.
Barbhaiya, RH; Shyu, WC, 1996
)
0.29
" Therefore, pharmacokinetic parameters could not be estimated for NOR-B and conjugated metabolites."( The pharmacokinetics of butorphanol and its metabolites at steady state following nasal administration in humans.
Barbhaiya, RH; Greene, DS; Shyu, WC; Vachharajani, NN, 1997
)
0.3
" There were no statistically significant differences in the pharmacokinetic parameters, Cmax, tmax, AUC, and t1/2, for butorphanol with or without metoclopramide."( Pharmacokinetic interaction between butorphanol nasal spray and oral metoclopramide in healthy women.
Barbhaiya, RH; Shyu, WC; Vachharajani, NN, 1997
)
0.3
" Pharmacokinetic variables were calculated, and changes in physical examination data, gastrointestinal tract transit time, and behavior were determined over time."( Pharmacokinetics and adverse effects of butorphanol administered by single intravenous injection or continuous intravenous infusion in horses.
Monroe, VL; Papich, MG; Roberts, MC; Sellon, DC, 2001
)
0.31
" Elimination half-life of butorphanol was brief (44."( Pharmacokinetics and adverse effects of butorphanol administered by single intravenous injection or continuous intravenous infusion in horses.
Monroe, VL; Papich, MG; Roberts, MC; Sellon, DC, 2001
)
0.31
" This 8-week inpatient study examined the ability of enadoline, a selective and high-efficacy kappa-agonist, and butorphanol, a mixed agonist with intermediate efficacy at both mu- and kappa-receptors, to reduce the direct pharmacodynamic effects and self-administration of intravenous cocaine in humans (n = 8)."( Enadoline and butorphanol: evaluation of kappa-agonists on cocaine pharmacodynamics and cocaine self-administration in humans.
Bigelow, GE; Geter-Douglas, B; Strain, EC; Walsh, SL, 2001
)
0.31
" Plasma butorphanol versus time curves were subjected to pharmacokinetic analysis."( Pharmacokinetics and pharmacodynamics of butorphanol in llamas after intravenous and intramuscular administration.
Boothe, DM; Carroll, GL; Hartsfield, SM; Hernandez, A; Martinez, EA; Spann, AC, 2001
)
0.31
" However, the possibility of a pharmacokinetic interaction and the safety of this regime have not been examined."( A pharmacokinetic interaction study between butorphanol and sumatriptan nasal sprays in healthy subjects: importance of the timing of butorphanol administration.
Boulton, DW; Nichola, PS; Shyu, WC; Vachharajani, NN, 2002
)
0.31
" A comparison is also presented between several methods based on animal pharmacokinetic data, using the same set of proprietary compounds, and it lends further support for the use of this method, as opposed to methods that require the gathering of pharmacokinetic data in laboratory animals."( Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY, 2004
)
0.32
" Pharmacokinetic parameters were determined using noncompartmental methods."( Pharmacokinetics of butorphanol tartrate administered from single-dose intranasal sprayer.
Archer, SM; Davis, GA; Rudy, AC; Wermeling, DP, 2004
)
0.32
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
"2- and 1-compartment models best fit the IV and IM pharmacokinetic data, respectively, in both species."( Pharmacokinetics of butorphanol tartrate in red-tailed hawks (Buteo jamaicensis) and great horned owls (Bubo virginianus).
Craigmill, AL; Hawkins, MG; Kass, PH; Riggs, SM; Stanley, SD; Taylor, IT, 2008
)
0.35
"In RTHs and GHOs, butorphanol was rapidly absorbed and distributed via all routes of administration; the drug's rapid terminal half-life indicated that published dosing intervals for birds may be inadequate in RTHs and GHOs."( Pharmacokinetics of butorphanol tartrate in red-tailed hawks (Buteo jamaicensis) and great horned owls (Bubo virginianus).
Craigmill, AL; Hawkins, MG; Kass, PH; Riggs, SM; Stanley, SD; Taylor, IT, 2008
)
0.35
"Data from 1 cat contained outliers and were excluded from pharmacokinetic analysis."( Pharmacokinetics of butorphanol in cats after intramuscular and buccal transmucosal administration.
Glerum, LE; Papich, MG; Wells, SM, 2008
)
0.35
" Terminal half-life after IV administration was much longer than half-life after IM administration (0."( Pharmacokinetics of butorphanol in horses after intramuscular injection.
Palmer, L; Papich, MG; Remund, B; Sellon, DC, 2009
)
0.35
" However, dosages used in treating elephants were often extrapolated from data in horses, with no pharmacokinetic information on the specific agents used in elephant species."( Pharmacokinetics and intramuscular bioavailability of a single dose of butorphanol in Asian elephants (Elephas maximus).
Hunter, RP; Isaza, R; Koch, DE; Tana, LM, 2010
)
0.36
" Plasma samples were analysed by a highly sensitive high-performance liquid chromatography with diode-array detection method and pharmacokinetic parameters were calculated from the mean pooled data."( Pharmacokinetics of butorphanol in broiler chickens.
Chambers, P; Gartrell, B; Johnson, C; Mitchinson, S; Singh, PM, 2011
)
0.37
"To determine the pharmacokinetic parameters of xylazine, ketamine, and butorphanol (XKB) administered IM and sodium salicylate (SAL) administered PO to calves and to compare drug effects on biomarkers of pain and distress following sham and actual castration and dehorning."( Pharmacokinetics and physiologic effects of intramuscularly administered xylazine hydrochloride-ketamine hydrochloride-butorphanol tartrate alone or in combination with orally administered sodium salicylate on biomarkers of pain in Holstein calves followi
Baldridge, SL; Coetzee, JF; Dritz, SS; Gehring, R; Havel, J; Kukanich, B; Reinbold, JB, 2011
)
0.37
" Plasma butorphanol concentrations were determined by high-performance liquid chromatography/tandem mass spectrometry, and pharmacokinetic parameters were calculated."( Pharmacokinetics of butorphanol after intravenous, intramuscular, and oral administration in Hispaniolan Amazon parrots (Amazona ventralis).
Barker, SA; Flammer, K; Guzman, DS; Paul-Murphy, JR; Tully, TN, 2011
)
0.37
" Mean±SD systemic clearance, steady-state volume of distribution, and terminal elimination half-life were 11."( Pharmacokinetics and pharmacodynamics of butorphanol following intravenous administration to the horse.
Arthur, RM; Casbeer, HC; Knych, HK; McKemie, DS, 2013
)
0.39
" Venous blood samples were collected at strategic time points and alfaxalone plasma concentrations were assayed using liquid chromatography-mass spectrometry (LC/MS) and analysed by noncompartmental pharmacokinetic analysis."( Plasma pharmacokinetics and pharmacodynamics of alfaxalone in neonatal foals after an intravenous bolus of alfaxalone following premedication with butorphanol tartrate.
Goodwin, W; Keates, H; Pasloske, K; Pearson, M; Ranasinghe, MG; Sauer, B, 2012
)
0.38
" For the pharmacokinetic analysis, butorphanol (6 mg/kg, IM) was administered in the pectoral muscles of each of 12 birds."( Evaluation of thermal antinociceptive effects and pharmacokinetics after intramuscular administration of butorphanol tartrate to American kestrels (Falco sparverius).
Drazenovich, TL; Guzman, DS; KuKanich, B; Olsen, GH; Paul-Murphy, JR; Willits, NH, 2014
)
0.4
" Pharmacokinetic analysis was performed by use of noncompartmental analysis."( Pharmacokinetics of butorphanol tartrate in a long-acting poloxamer 407 gel formulation administered to Hispaniolan Amazon parrots (Amazona ventralis).
Beaufrère, H; Guzman, DS; Knych, HK; Laniesse, D; Mosley, C; Paul-Murphy, JR; Smith, DA, 2017
)
0.46
" Pharmacokinetic analysis was performed using noncompartmental analysis and a commercially available software program."( Pharmacokinetics of butorphanol tartrate in a poloxamer P407 gel formulation administered to orange-winged Amazon parrots (Amazona amazonica).
Douglas, JM; Knych, H; Mikoni, N; Paul-Murphy, JR; Sanchez-Migallon Guzman, D, 2022
)
0.72
" Cmax and tmax were 346."( Pharmacokinetics of butorphanol tartrate in a poloxamer P407 gel formulation administered to orange-winged Amazon parrots (Amazona amazonica).
Douglas, JM; Knych, H; Mikoni, N; Paul-Murphy, JR; Sanchez-Migallon Guzman, D, 2022
)
0.72
" Absorption followed a pharmacokinetic profile compatible with a sustained-release drug."( Pharmacokinetics of butorphanol tartrate in a poloxamer P407 gel formulation administered to orange-winged Amazon parrots (Amazona amazonica).
Douglas, JM; Knych, H; Mikoni, N; Paul-Murphy, JR; Sanchez-Migallon Guzman, D, 2022
)
0.72
"7 ml/min/kg, the mean terminal half-life was 82."( Pharmacokinetics of intravenous propofol in southern white rhinoceros (Ceratotherium simum simum) after intramuscular etorphine-butorphanol-medetomidine-azaperone.
Berlin, ER; Clancy, MM; Ferris, RL; Howard, LL; Kinney, ME; Knych, HK; Mama, KR; Perrin, KL; Phair, KA, 2023
)
0.91
"This study provides pharmacokinetic data and insight into the effects of propofol in rhinoceros anesthetized using etorphine, butorphanol, medetomidine, and azaperone."( Pharmacokinetics of intravenous propofol in southern white rhinoceros (Ceratotherium simum simum) after intramuscular etorphine-butorphanol-medetomidine-azaperone.
Berlin, ER; Clancy, MM; Ferris, RL; Howard, LL; Kinney, ME; Knych, HK; Mama, KR; Perrin, KL; Phair, KA, 2023
)
0.91

Compound-Compound Interactions

Butorphanol promoted a higher sedative effect than nalbuphine when alone and combined with acepromazine. Butorphanol tartrate combined with hydromorphone can reduce analgesic use of butorphanol during dressing change.

ExcerptReferenceRelevance
"The sedative effects of the low dose of butorphanol combined with diazepam during spinal-epidural (H-type) anesthesia were studied in 20 urological or gynecological patients of ASA class I or II."( [The sedative effects of a low dose of butorphanol combined with diazepam during spinal-epidural anesthesia (H-type anesthesia)].
Abe, Y; Hanaoka, K; Hiraishi, T; Ide, Y; Sugiyama, A; Yajima, C, 1989
)
0.28
"A xylazine and butorphanol drug combination produced minimal and transient hemodynamic effects and no significant respiratory depression when administered to 6 healthy horses."( A new analgesic drug combination in the horse.
Muir, WW; Robertson, JT, 1983
)
0.27
"The efficacy of spinal anesthesia with lidocaine (1 mg/kg) combined with moradol (0."( [Spinal anesthesia with lidocaine combined with moradol].
Kheĭfets, VKh; Maksimov, AV,
)
0.13
"To evaluate anesthetic effects of tiletamine-zolazepam (TZ), alone or in combination with butorphanol, in goats undergoing laparotomy for embryo collection."( Anesthetic effects of tiletamine-zolazepam, alone or in combination with butorphanol, in goats.
Carroll, GL; Hambleton, R; Hartsfield, SM, 1997
)
0.3
"The present study examined the effects of SNC80 alone and in combination with the mu opioid agonists, morphine, butorphanol, and buprenorphine to determine whether SNC80 would enhance their antinociceptive effects."( Antinociceptive effects of the selective delta opioid agonist SNC80 alone and in combination with mu opioids in the squirrel monkey titration procedure.
Allen, RM; Dykstra, LA; Granger, AL; Rice, KC; Zhang, X, 2002
)
0.31
"To assess the cardiovascular effects (arterial blood pressure, heart rate, and metabolic acid-base status) of three doses (MAC multiples) of isoflurane alone and combined with butorphanol in the green iguana (Iguana iguana)."( The cardiovascular dose-response effects of isoflurane alone and combined with butorphanol in the green iguana (Iguana iguana).
Dyson, D; Mosley, CA; Smith, DA, 2004
)
0.32
" The degree of cardiovascular depression was not significantly different when isoflurane was combined with butorphanol."( The cardiovascular dose-response effects of isoflurane alone and combined with butorphanol in the green iguana (Iguana iguana).
Dyson, D; Mosley, CA; Smith, DA, 2004
)
0.32
" Use of morphine and butorphanol in combination with alpha2 agonists should be further investigated to assess their analgesic effects."( Comparison of morphine and butorphanol as pre-anaesthetic agents in combination with romifidine for field castration in ponies.
Brearley, JC; Corletto, F; Raisis, AA, 2005
)
0.33
"To compare the effects of morphine (MOR), methadone (MET), butorphanol (BUT) and tramadol (TRA), in combination with acepromazine, on sedation, cardiorespiratory variables, body temperature and incidence of emesis in dogs."( Comparative study on the sedative effects of morphine, methadone, butorphanol or tramadol, in combination with acepromazine, in dogs.
Assis, HM; Campagnol, D; Junior, AR; Monteiro, ER; Quitzan, JG, 2009
)
0.35
" Continuous basal infusion of drugs combined with standard patient-controlled analgesia (PCA) is considered to be an effective means of postoperative acute pain management."( Continuous infusion of butorphanol combined with intravenous morphine patient-controlled analgesia after total abdominal hysterectomy: a randomized, double-blind controlled trial.
Guo, X; Liu, Y; Shen, X; Wang, F; Xu, S, 2009
)
0.35
"Basal infusion of butorphanol combined with intravenous morphine PCA in patients undergoing abdominal hysterectomy shows effective analgesia with sedation and fewer side effects."( Continuous infusion of butorphanol combined with intravenous morphine patient-controlled analgesia after total abdominal hysterectomy: a randomized, double-blind controlled trial.
Guo, X; Liu, Y; Shen, X; Wang, F; Xu, S, 2009
)
0.35
"To determine the anesthetic-sparing effects of perzinfotel when administered as a preanesthetic via IV, IM, or SC routes or IM in combination with butorphanol."( Effects of perzinfotel on the minimum alveolar concentration of isoflurane in dogs when administered as a preanesthetic via various routes or in combination with butorphanol.
del Rio, CL; Muir, WW; Pollet, RA; Zwijnenberg, RJ, 2010
)
0.36
"To compare the efficacy and cardiorespiratory effects of dexmedetomidine-ketamine in combination with butorphanol, hydromorphone, or buprenorphine with or without reversal by atipamezole in cats undergoing castration."( Evaluation of dexmedetomidine and ketamine in combination with various opioids as injectable anesthetic combinations for castration in cats.
Austin, BR; Barletta, M; Ko, JC; Krimins, RA; Payton, ME; Weil, AB, 2011
)
0.37
"To investigate the safety, sedative and analgesic properties of methadone in combination with acepromazine prior to neutering in cats."( Methadone in combination with acepromazine as premedication prior to neutering in the cat.
Bortolami, E; Murrell, JC; Slingsby, LS, 2013
)
0.39
"Cats received one of three opioids combined with acepromazine (0."( Methadone in combination with acepromazine as premedication prior to neutering in the cat.
Bortolami, E; Murrell, JC; Slingsby, LS, 2013
)
0.39
"Methadone provided comparable sedation and analgesia to both buprenorphine and butorphanol when combined with acepromazine."( Methadone in combination with acepromazine as premedication prior to neutering in the cat.
Bortolami, E; Murrell, JC; Slingsby, LS, 2013
)
0.39
"The aim of the present study is to explore the impact of butorphanol in combination with ketamine via nasal inhalation (NI) on neuropathic pain induced by chronic constriction injury (CCI) to the sciatic nerve in a rat model."( Nasal inhalation of butorphanol in combination with ketamine quickly elevates the mechanical pain threshold in the model of chronic constriction injury to the sciatic nerve of rat.
Chen, F; Chen, S; Chen, Z; Li, Z; Wang, L; Zhai, D; Zhou, X, 2014
)
0.4
"NI of butorphanol in combination with ketamine quickly elevates the mechanical pain threshold in a rat neuropathic pain model induced by CCI to the sciatic nerve."( Nasal inhalation of butorphanol in combination with ketamine quickly elevates the mechanical pain threshold in the model of chronic constriction injury to the sciatic nerve of rat.
Chen, F; Chen, S; Chen, Z; Li, Z; Wang, L; Zhai, D; Zhou, X, 2014
)
0.4
"To compare the sedative effects of an intramuscular (IM) low dose of medetomidine in combination with butorphanol or methadone in dogs."( The sedative effects of intramuscular low-dose medetomidine in combination with butorphanol or methadone in dogs.
Canfrán, S; Costa-Farré, C; Gómez de Segura, IA; Puighibet, Z; Santos, L, 2015
)
0.42
"To evaluate the echocardiographic variables and sedation after two dosages of dexmedetomidine combined with butorphanol in healthy dogs."( Sedative and echocardiographic effects of dexmedetomidine combined with butorphanol in healthy dogs.
Hassen, KM; Kellihan, HB; Smith, LJ; Stepien, RL, 2015
)
0.42
"The pharmacological effects of intramuscular (IM) administration of alfaxalone combined with medetomidine and butorphanol were evaluated in 6 healthy beagle dogs."( The pharmacological effects of intramuscular administration of alfaxalone combined with medetomidine and butorphanol in dogs.
Fukui, S; Hatakeyama, N; Ishizuka, T; Itami, T; Miyoshi, K; Pasloske, K; Sano, T; Tamura, J; Yamashita, K, 2016
)
0.43
"Objectives Cardiorespiratory parameters and anaesthesia quality in cats anaesthetised with either intramuscular (IM) alfaxalone or ketamine both combined with dexmedetomidine and butorphanol for castration were evaluated."( Comparison of intramuscular alfaxalone and ketamine combined with dexmedetomidine and butorphanol for castration in cats.
Broussaud, S; Khenissi, L; Nikolayenkova-Topie, O; Touzot-Jourde, G, 2017
)
0.46
"The aim of this study was to evaluate the efficacy of dexmedetomidine in combination with sufentanil or butorphanol for postoperative analgesia in patients undergoing laparoscopic resection of a gastrointestinal tumor."( Evaluation of dexmedetomidine in combination with sufentanil or butorphanol for postoperative analgesia in patients undergoing laparoscopic resection of gastrointestinal tumors: A quasi-experimental trial.
Chen, QH; Hu, Q; Wang, WX; Zhang, XK, 2016
)
0.43
" Methods Using a prospective, randomised, blinded design, 40 client-owned adult cats were assigned to receive IM dexmedetomidine (10 µg/kg) combined with either butorphanol (0."( Comparison of intramuscular butorphanol and buprenorphine combined with dexmedetomidine for sedation in cats.
Bhalla, RJ; Leece, EA; Trimble, TA; Vettorato, E, 2018
)
0.48
"To assess quality of sedation following intramuscular (IM) injection of two doses of alfaxalone in combination with butorphanol in cats."( Intramuscular injection of alfaxalone in combination with butorphanol for sedation in cats.
Archer, E; Deutsch, J; Jolliffe, C; Leece, EA, 2017
)
0.46
"Each dog was treated four times: physiological saline (1 mL) combined with nalbuphine (0."( Comparison of the sedative effects of nalbuphine and butorphanol, alone or in combination with acepromazine in dogs.
Coelho, CM; Gomes, VH; Marques, JL; Oliveira, RL; Silva, MF, 2018
)
0.48
"Butorphanol promoted a higher sedative effect than nalbuphine when alone and combined with acepromazine."( Comparison of the sedative effects of nalbuphine and butorphanol, alone or in combination with acepromazine in dogs.
Coelho, CM; Gomes, VH; Marques, JL; Oliveira, RL; Silva, MF, 2018
)
0.48
"OBJECTIVE To evaluate cardiopulmonary, sedative, and antinociceptive effects of dexmedetomidine combined with commonly administered opioids in dogs."( Effects of dexmedetomidine combined with commonly administered opioids on clinical variables in dogs.
Auckburally, A; de Mattos-Junior, E; Garcia, DO; Honsho, CS; Nishimura, LT; Santilli, J; Vieira, BHB, 2018
)
0.48
"Opioids can be combined with alpha-2-adrenoreceptor agonists to sedate dogs for radiography."( Comparison of sedation in dogs: methadone or butorphanol in combination with dexmedetomidine intravenously.
Bhalla, RJ; Leece, EA; Trimble, T, 2018
)
0.48
"IV butorphanol provides more effective sedation at 10 minutes than methadone, in combination with dexmedetomidine."( Comparison of sedation in dogs: methadone or butorphanol in combination with dexmedetomidine intravenously.
Bhalla, RJ; Leece, EA; Trimble, T, 2018
)
0.48
"The aim of this study was to investigate the sedative effects of medetomidine in combination with midazolam or butorphanol for routine imaging procedures in dogs."( Randomised clinical trial comparing clinically relevant sedation outcome measures in dogs after intramuscular administration of medetomidine in combination with midazolam or butorphanol for routine diagnostic imaging procedures.
Le Chevallier, D; Murrell, JC; Slingsby, L, 2018
)
0.48
"The objective of the study was to evaluate the duration of the effects of sedation with detomidine and detomidine combined with a low dose of butorphanol on the movement patterns of horses."( A kinematic comparison of the locomotor pattern of horses sedated with detomidine alone and in combination with low doses of butorphanol.
Frigerio, MA; Gómez Cisneros, D; López-Sanromán, J; Manso-Díaz, G; Santiago Llorente, I, 2019
)
0.51
"To evaluate the sedative and cardiorespiratory effects of IM administration of alfaxalone and butorphanol combined with acepromazine, midazolam, or dexmedetomidine in dogs."( Sedative and cardiorespiratory effects of intramuscular administration of alfaxalone and butorphanol combined with acepromazine, midazolam, or dexmedetomidine in dogs.
Aarnes, TK; Bednarski, RM; Cremer, J; Lerche, P; Murdock, MA; Riccó Pereira, CH, 2020
)
0.56
"4 mg/kg] combined with acepromazine [0."( Sedative and cardiorespiratory effects of intramuscular administration of alfaxalone and butorphanol combined with acepromazine, midazolam, or dexmedetomidine in dogs.
Aarnes, TK; Bednarski, RM; Cremer, J; Lerche, P; Murdock, MA; Riccó Pereira, CH, 2020
)
0.56
"This study aimed to explore the effect of patient-controlled intravenous analgesia (PCIA) using tramadol combined with butorphanol on uterine cramping pain in women undergoing repeat caesarean section."( The analgesic effect of tramadol combined with butorphanol on uterine cramping pain after repeat caesarean section: a randomized, controlled, double-blind study.
Cai, L; Cai, Q; Chen, W; Fan, M; Gong, H, 2020
)
0.56
" PCIA using tramadol combined with butorphanol or sufentanil was randomly performed for postoperative pain control."( The analgesic effect of tramadol combined with butorphanol on uterine cramping pain after repeat caesarean section: a randomized, controlled, double-blind study.
Cai, L; Cai, Q; Chen, W; Fan, M; Gong, H, 2020
)
0.56
"PCIA using tramadol combined with butorphanol provided a better analgesic effect and accelerated postoperative rehabilitation compared with sufentanil, and may be an optimal analgesic strategy for women undergoing repeat caesarean section."( The analgesic effect of tramadol combined with butorphanol on uterine cramping pain after repeat caesarean section: a randomized, controlled, double-blind study.
Cai, L; Cai, Q; Chen, W; Fan, M; Gong, H, 2020
)
0.56
"To evaluate the feasibility of gastroduodenoscopy in dogs premedicated with acepromazine in combination with butorphanol or methadone."( Comparison of the effects of methadone and butorphanol combined with acepromazine for canine gastroduodenoscopy.
Candido, MV; Casoni, D; Lepajoe, J; Salla, KM; Spillmann, T, 2020
)
0.56
"In our study population, the effects of methadone and butorphanol when combined with acepromazine were comparable."( Comparison of the effects of methadone and butorphanol combined with acepromazine for canine gastroduodenoscopy.
Candido, MV; Casoni, D; Lepajoe, J; Salla, KM; Spillmann, T, 2020
)
0.56
"The present study aimed to determine the effectiveness of intravenous dexmedetomidine of different concentrations and to evaluate its maternal and neonatal safety when combined with butorphanol in parturients undergoing cesarean section."( The Effectiveness and Safety of Intravenous Dexmedetomidine of Different Concentrations Combined with Butorphanol for Post-Caesarean Section Analgesia: A Randomized Controlled Trial.
Cao, X; Gao, M; Hu, Y; Liu, C; Liu, S; Peng, P; Yang, C, 2021
)
0.62
"This study aimed to compare the sedation and analgesic effects of butorphanol alone and butorphanol in combination with dexmedetomidine on dressing changes in adult burn patients."( Butorphanol in combination with dexmedetomidine provides efficient pain management in adult burn patients.
Ding, X; Liu, C; Luo, Y; Shi, L; Yan, Z, 2021
)
0.62
" In the control group, butorphanol combined with saline was injected into the body via venous route during dressing change."( Butorphanol in combination with dexmedetomidine provides efficient pain management in adult burn patients.
Ding, X; Liu, C; Luo, Y; Shi, L; Yan, Z, 2021
)
0.62
"Butorphanol combined with dexmedetomidine can reduce analgesic use of butorphanol during dressing change."( Butorphanol in combination with dexmedetomidine provides efficient pain management in adult burn patients.
Ding, X; Liu, C; Luo, Y; Shi, L; Yan, Z, 2021
)
0.62
" The aim of this study was to evaluate in an avian species the influence of isoflurane and sevoflurane on BIS, each at different minimum anaesthetic concentrations (MAC) multiples, alone or combined with butorphanol or medetomidine."( Effects of isoflurane and sevoflurane alone and in combination with butorphanol or medetomidine on the bispectral index in chickens.
Hatt, JM; Martin Jurado, O; Velasco Gallego, ML, 2021
)
0.62
"To evaluate the effects of dexmedetomidine alone or in combination with different opioids on intraocular pressure (IOP) in dogs."( Effects of dexmedetomidine alone or in combination with opioids on intraocular pressure in healthy Beagle dogs.
Cabrini, TM; Honsho, CS; Mattos-Junior, E; Nishimura, LT; Pypendop, BH, 2021
)
0.62
"Dexmedetomidine alone or in combination with butorphanol, meperidine, methadone, nalbuphine or tramadol resulted in decreased IOP for 120 minutes in dogs."( Effects of dexmedetomidine alone or in combination with opioids on intraocular pressure in healthy Beagle dogs.
Cabrini, TM; Honsho, CS; Mattos-Junior, E; Nishimura, LT; Pypendop, BH, 2021
)
0.62
"This study aimed to investigate the clinical effect of ultrasound-guided ropivacaine combined with butorphanol continuous paravertebral block in preventing postoperative pain syndrome of breast cancer."( Study of ultrasound-guided ropivacaine combined with butorphanol continuous paravertebral block to prevent pain syndrome by evaluating ccl2 gene expression after radical mastectomy.
Cui, W; Ji, X; Liu, X; Shan, S; Wang, L; Zhang, B, 2022
)
0.72
"To evaluate the analgesic effect of butorphanol tartrate combined with hydromorphone on the patients with cesarean section, we conducted a prospective cohort study."( Analgesic effect of butorphanol tartrate combined with hydromorphone on patients with cesarean section: A prospective cohort study.
Gong, X; Xie, S; Zhang, G; Zhang, Y, 2022
)
0.72
" This study aimed to compare the analgesic effects of tramadol alone and combined with butorphanol or flurbiprofen axetil after a cesarean section."( Analgesic outcomes of tramadol alone and in combination with Butorphanol or Flurbiprofen Axetil after cesarean section: a retrospective study with propensity score matching analysis.
Bao, X; Deng, Q; Li, H; Liang, Y; Liu, W; Peng, J; Tan, D; Wu, Z; Yan, G; Yang, G, 2022
)
0.72
" Patients were allocated to 2 groups based on the postoperative pain treatment they received: treatment group (administered butorphanol combined with sufentanil), and control group (administered conventional sufentanil analgesia)."( Analgesic efficacy of butorphanol combined with sufentanil after heart valve surgery: A propensity score-matching analysis.
Cheng, X; Du, C; Guo, S; Jiang, X; Zhang, W, 2022
)
0.72

Bioavailability

The onset of action and systemic bioavailability of butorphanol following transnasal delivery are similar to those after parenteral administration. Butorphanol was significantly higher (approximately 20%) in patients with hepatic impairment.

ExcerptReferenceRelevance
" The onset of action and systemic bioavailability of butorphanol following transnasal delivery are similar to those after parenteral administration."( Transnasal butorphanol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in acute pain management.
Benfield, P; Gillis, JC; Goa, KL, 1995
)
0.29
"The absolute bioavailability (f) and pharmacokinetics of transnasal butorphanol were evaluated in patients experiencing rhinitis."( The absolute bioavailability of transnasal butorphanol in patients experiencing rhinitis.
Barbhaiya, RH; Pittman, KA; Robinson, DS; Shyu, WC, 1993
)
0.29
"A series of three-way crossover randomized studies were conducted to evaluate the absolute bioavailability of butorphanol, a potent agonist-antagonist analgesic, from transnasal, sublingual, and buccal disk formulations in order to identify a practical alternative to oral administration."( Biopharmaceutical evaluation of transnasal, sublingual, and buccal disk dosage forms of butorphanol.
Barbhaiya, RH; Gammans, RE; Mayol, RF; Pfeffer, M; Pittman, KA; Shyu, WC, 1993
)
0.29
"The objective of the study was to investigate the effects of hepatic impairment on the absolute transnasal bioavailability and pharmacokinetics of butorphanol."( The absolute bioavailability and pharmacokinetics of butorphanol nasal spray in patients with hepatic impairment.
Barbhaiya, RH; Garnett, WR; Morgenthien, EA; Shyu, WC; Vachharajani, NN, 1996
)
0.29
" The absolute transnasal bioavailability of butorphanol was significantly higher (approximately 20%) in patients with hepatic impairment."( The absolute bioavailability and pharmacokinetics of butorphanol nasal spray in patients with hepatic impairment.
Barbhaiya, RH; Garnett, WR; Morgenthien, EA; Shyu, WC; Vachharajani, NN, 1996
)
0.29
"The bioavailability and tolerability of single doses of intranasal butorphanol tartrate using a single-dose, metered sprayer were studied."( Bioavailability of intranasal butorphanol administered from a single-dose sprayer.
Archer, SM; Davis, GA; Rudy, AIa; Wermeling, DP, 2005
)
0.33
"Intranasal butorphanol 1 and 2 mg administered using unit dose sprayers had a mean bioavailability of approximately 80%, which is higher than the percentage reported with the commercially available multidose product (61-69%)."( Bioavailability of intranasal butorphanol administered from a single-dose sprayer.
Archer, SM; Davis, GA; Rudy, AIa; Wermeling, DP, 2005
)
0.33
"Single-dose intranasal butorphanol was rapidly absorbed and had high absolute bioavailability in healthy volunteers."( Bioavailability of intranasal butorphanol administered from a single-dose sprayer.
Archer, SM; Davis, GA; Rudy, AIa; Wermeling, DP, 2005
)
0.33
" Bioavailability of butorphanol administered IM was 97."( Pharmacokinetics of butorphanol tartrate in red-tailed hawks (Buteo jamaicensis) and great horned owls (Bubo virginianus).
Craigmill, AL; Hawkins, MG; Kass, PH; Riggs, SM; Stanley, SD; Taylor, IT, 2008
)
0.35
" Bioavailability was 66."( Pharmacokinetics of butorphanol and evaluation of physiologic and behavioral effects after intravenous and intramuscular administration to neonatal foals.
Arguedas, MG; Farnsworth, KD; Hines, MT; Papich, MG; Sellon, DC,
)
0.13
"To determine the pharmacokinetics of butorphanol in cats following IM and buccal transmucosal (BTM) administration, to determine the relative bioavailability of butorphanol following BTM administration, and to extrapolate a plasma concentration associated with antinociception on the basis of existing data from pharmacologic studies of butorphanol in cats."( Pharmacokinetics of butorphanol in cats after intramuscular and buccal transmucosal administration.
Glerum, LE; Papich, MG; Wells, SM, 2008
)
0.35
" bioavailability was 37%."( Pharmacokinetics and intramuscular bioavailability of a single dose of butorphanol in Asian elephants (Elephas maximus).
Hunter, RP; Isaza, R; Koch, DE; Tana, LM, 2010
)
0.36
" The goals of this study in the Hispaniolan Amazon parrot (Amazona ventralis) were to evaluate the pharmacokinetics of butorphanol tartrate after intravenous (IV), intramuscular (IM), and oral (PO) administration and to determine the bioavailability of butorphanol tartrate after oral administration."( Pharmacokinetics of butorphanol after intravenous, intramuscular, and oral administration in Hispaniolan Amazon parrots (Amazona ventralis).
Barker, SA; Flammer, K; Guzman, DS; Paul-Murphy, JR; Tully, TN, 2011
)
0.37
" Bioavailability was 87%."( Pharmacokinetics and pharmacodynamics comparison between subcutaneous and intravenous butorphanol administration in horses.
Chiavaccini, L; Claude, AK; Langston, VC; Lee, JH; Meyer, RE; Ross, MK, 2015
)
0.42
" SC-bicarbonate had lower bioavailability (61%) relative to SC, with no sustained release, and the CRI mean steady-state plasma concentration was 43."( Dosing protocols to increase the efficacy of butorphanol in dogs.
Gray, M; KuKanich, B; KuKanich, K; Lai, P; Springfield, D, 2022
)
0.72

Dosage Studied

Butorphanol had no action on DA metabolites in the entorhinal, prefrontal, pyriform and cingulate cortices and in the olfactory tubercle. Adverse gastrointestinal tract effects were less apparent during continuous 24-hour infusion of butorphanol.

ExcerptRelevanceReference
"The chemistry, pharmacology, uses, side effects, pharmacokinetics and dosage of butorphanol tartrate, a narcotic analgesic with antagonist properties, are reviewed."( Drug therapy reviews: evaluation of butorphanol tartrate.
Ameer, B; Salter, FJ, 1979
)
0.26
"8 mg/kg the only dosage that was significantly different from control responses at the 45-minute interval."( Dose response to butorphanol administered subcutaneously to increase visceral nociceptive threshold in dogs.
Adams, T; Durham, RA; Rech, RH; Richter, MA; Sawyer, DC; Striler, EL, 1991
)
0.28
"This study was undertaken to compare the effectiveness and safety of three dosage levels of butorphanol in 52 patients with acute, severe migraine headache."( Dose effectiveness and safety of butorphanol in acute migraine headache.
Elenbaas, RM; Evens, RP; Gratton, M; Iacono, CU; Koellner, KJ; Pribble, JP; Racz, G, 1991
)
0.28
" Neither dosing regimen caused significant changes in right atrial pressure, heart rate, pulmonary vascular resistance, or pulmonary capillary wedge pressure."( The cardiovascular response of sheep to tiletamine-zolazepam and butorphanol tartrate anesthesia.
Howard, BW; Januszkiewicz, AJ; Lagutchik, MS; Martin, DG,
)
0.13
" Butorphanol resulted in partial reversal of sedation at both dosage levels."( Reversal of oxymorphone sedation by naloxone, nalmefene, and butorphanol.
Anderson, GI; Doherty, T; Dyson, DH; McDonell, WN,
)
0.13
" Physiologic measures and subject- and observer-rated behavioral responses were measured before dosing and for 2 hr after drug administration."( Butorphanol-precipitated withdrawal in opioid-dependent human volunteers.
Bigelow, GE; Liebson, IA; Preston, KL, 1988
)
0.27
" Nalbuphine was not consistently identified as either pentazocine or hydromorphone and produced relatively flat dose-response functions on most of the subjective effect measures."( Drug discrimination in human postaddicts: agonist-antagonist opioids.
Bickel, WK; Bigelow, GE; Liebson, IA; Preston, KL, 1989
)
0.28
" Dosage titration increased efficacy to 85."( Butorphanol as a dental premedication in the mentally retarded.
Fidone, G; Gorday, M; Jann, MW; Rostedt, RR, 1987
)
0.27
" But a number of kappa agonists, including bremazocine, tifluadom, ethylketocyclazocine, ketocyclazocine, U-50,488 and Win 42,610 all depressed contractions, producing parallel dose-response curves."( Profile of activity of kappa receptor agonists in the rabbit vas deferens.
Hayes, A; Kelly, A, 1985
)
0.27
"Systemic administration of beta-funaltrexamine (beta-FNA) 24 hr before analgesic testing produced approximately a 10-fold parallel shift in the dose-response curves of the prototypic mu agonists morphine, I-methadone, fentanyl and etorphine in the mouse abdominal constriction test."( Use of beta-funaltrexamine to determine mu opioid receptor involvement in the analgesic activity of various opioid ligands.
Hynes, MD; Leander, JD; Reel, JK; Zimmerman, DM, 1987
)
0.27
" A tentative dosage range has been established."( Butorphanol improves CO2 response and ventilation after fentanyl anesthesia.
Bjurstrom, RL; Bowdle, TA; Greichen, SL; Schoene, RB, 1987
)
0.27
" Our data suggest that young and old subjects attain similar plasma concentrations after single doses; however, longer dosing intervals may be necessary for multiple dosing in the elderly."( Influence of age on the pharmacokinetics of butorphanol.
Higbee, M; Maesner, J; Ramsey, R; Wood, J, 1988
)
0.27
" While butorphanol had a bell-shaped dose-response relationship for elevation of DA metabolites in the striatum, it had no action on DA metabolites in the entorhinal, prefrontal, pyriform and cingulate cortices and in the olfactory tubercle."( Agonist action of the agonist/antagonist analgesic butorphanol on dopamine metabolism in the nucleus accumbens of the rat.
Iyengar, S; Kim, HS; Wood, PL, 1987
)
0.27
" When the scores derived from the categorized ratings 1 hour after drug dosing (generally the time of peak effect) were analyzed, there was little difference whether a parametric or nonparametric approach was taken."( Reassessment of verbal and visual analog ratings in analgesic studies.
Littman, GS; Schneider, BE; Walker, BR, 1985
)
0.27
" Dose-response curves were constructed using the rat tail pressure test for analgesia which indicated a rank order of potency of buprenorphine much greater than morphine greater than butorphanol greater than xorphanol = nalbuphine."( Physical dependence induced by opiate partial agonists in the rat.
Howlett, GJ; McCarthy, PS, 1984
)
0.27
"Agonist/antagonist (Ag/Ant) analgesics possess bell-shaped dose-response curves with regard to nigrostriatal dopamine (DA) metabolism in the rat."( Agonist/antagonist analgesics and nigrostriatal dopamine metabolism in the rat: evidence for receptor dualism.
McQuade, P; Richard, JW; Thakur, M; Wood, PL, 1983
)
0.27
" Reports of high intrabiliary pressures and bizarre cholangiograms for patients under such anesthesia led us to investigate the specific effects on intrabiliary pressure of morphine sulfate, fentanyl and butorphanol tartrate, each at two different dosage levels."( Effects of butorphanol, fentanyl and morphine on the intrabiliary pressure of guinea pigs.
Aldrete, JA; Franatovic, Y; Romo-Salas, F, 1980
)
0.26
" In terms of butorphanol and morphine tolerance, a parallel rightward shift in the dose-response curve was produced with the degree of shift proportional to the log of the infusion dose."( Tolerance development to butorphanol: comparison with morphine.
Feng, YZ; Ho, IK; Hoskins, B; Jaw, SP; Tseng, YT, 1994
)
0.29
" Continuous ICV infusion with butorphanol produced a marked rightward shift of the antinociceptive dose-response curve resulting from U-50,488 challenge."( Crosstolerance between butorphanol and morphine in rats.
Feng, YZ; Ho, IK; Hoskins, B; Narita, M; Tseng, YT, 1994
)
0.29
" Uterine contraction patterns for the first hour after dosing were unchanged, and the duration of the first and second stages of labor were not different between the two groups."( Double-blind comparison of intravenous butorphanol (Stadol) and fentanyl (Sublimaze) for analgesia during labor.
Atkinson, BD; Christensen, HD; Rayburn, WF; Truitt, LJ; Turnbull, GL; Wlodaver, A, 1994
)
0.29
"Cisplatin was administered at a dosage of 50 mg/m2 of body surface to 69 dogs with various neoplasms."( Evaluation of butorphanol and cyproheptadine for prevention of cisplatin-induced vomiting in dogs.
Berg, J; Dennis, RA; L'Heureux, DA; Moore, AS; Rand, WM, 1994
)
0.29
" The age- and sex-related changes in the pharmacokinetics of transnasal butorphanol are not large enough to necessitate dosage differences."( The effects of age and sex on the systemic availability and pharmacokinetics of transnasal butorphanol.
Barbhaiya, RH; Morgenthien, EA; Pittman, KA; Shyu, WC, 1994
)
0.29
" Subsequent dosing was flexible depending on response to the initial dose."( Effectiveness of transnasal butorphanol for the treatment of musculoskeletal pain.
Feied, CF; Ghezzi, KT; Hunt, DM; Rosenthal, RE; Sanford, SM; Scott, JL; Shesser, RF; Smith, JP; Smith, MS, 1994
)
0.29
" Based on the results of these studies, transnasal dosage form of butorphanol was selected for further clinical trials of treatment of moderate to severe pain."( Biopharmaceutical evaluation of transnasal, sublingual, and buccal disk dosage forms of butorphanol.
Barbhaiya, RH; Gammans, RE; Mayol, RF; Pfeffer, M; Pittman, KA; Shyu, WC, 1993
)
0.29
" The values of maximum concentration, minimum concentration, and area under the concentration versus time curve from time zero to the dosing interval [AUC(0-tau)] increased as the administered dose increased in a dose-proportional manner."( Multiple-dose phase I study of transnasal butorphanol.
Barbhaiya, RH; Pittman, KA; Robinson, D; Shyu, WC, 1993
)
0.29
" The new nasal spray dosage form offers a similar degree of efficacy with a rapid onset of action."( Efficacy of transnasal butorphanol tartrate in postepisiotomy pain: a model to assess analgesia.
Jones, MM; Joyce, TH; Kubicek, MF; Skjonsby, BS,
)
0.13
" However, the subsequent dosing intervals for butorphanol should be prolonged."( The absolute bioavailability and pharmacokinetics of butorphanol nasal spray in patients with hepatic impairment.
Barbhaiya, RH; Garnett, WR; Morgenthien, EA; Shyu, WC; Vachharajani, NN, 1996
)
0.29
" Butorphanol nasal spray and cimetidine can be co-administered without any adjustment of dosage for either drug."( Lack of pharmacokinetic interaction between butorphanol nasal spray and cimetidine.
Barbhaiya, RH; Shyu, WC, 1996
)
0.29
" Six hours afterwards, each rat was challenged once with one of the differing it butorphanol doses to construct dose-response curves."( Visceral analgesic tolerance to intrathecal butorphanol in rats.
Eichhorn, JH; He, Z; Ho, IK; Tsang, BK; Wongchanapai, W, 1998
)
0.3
" The butorphanol-infused groups showed dose-response shifts, demonstrating the development of tolerance to this visceral analgesia."( Visceral analgesic tolerance to intrathecal butorphanol in rats.
Eichhorn, JH; He, Z; Ho, IK; Tsang, BK; Wongchanapai, W, 1998
)
0.3
" Buprenorphine at the dosage used did not change the threshold to electrical stimulus."( Analgesic effects of butorphanol and buprenorphine in conscious African grey parrots (Psittacus erithacus erithacus and Psittacus erithacus timneh).
Brunson, DB; Miletic, V; Paul-Murphy, JR, 1999
)
0.3
" Dose-response and time-course determinations were performed with various opioids."( Sex-related differences in the antinociceptive effects of opioids: importance of rat genotype, nociceptive stimulus intensity, and efficacy at the mu opioid receptor.
Barrett, AC; Bowman, JR; Cook, CD; Picker, MJ; Roach, EL, 2000
)
0.31
"This single-dose, double-blind, parallel-group, dose-response trial compared the efficacy and safety of 4 doses of intranasally administered butorphanol tartrate and placebo in controlling moderate to severe pain after the removal of impacted third molars in 151 patients."( Analgesic efficacy of intranasal butorphanol (Stadol NS) in the treatment of pain after dental impaction surgery.
Cooper, SA; Desjardins, PJ; Norris, LH; Reynolds, DC, 2000
)
0.31
"A linear dose-response regression (P < or = ."( Analgesic efficacy of intranasal butorphanol (Stadol NS) in the treatment of pain after dental impaction surgery.
Cooper, SA; Desjardins, PJ; Norris, LH; Reynolds, DC, 2000
)
0.31
" Self-administration of cocaine was readily initiated according to an inverted U-shaped unit dose-response curve."( Influence of buprenorphine, butorphanol and nalbuphine on the initiation of intravenous cocaine self-administration in drug naive mice.
Gerrits, MA; Kuzmin, AV; van Ree, JM; Zvartau, EE, 2000
)
0.31
" Adverse gastrointestinal tract effects were less apparent during continuous 24-hour infusion of butorphanol at a dosage that resulted in a mean plasma concentration of 29 ng/ml, compared with effects after a single IV injection."( Pharmacokinetics and adverse effects of butorphanol administered by single intravenous injection or continuous intravenous infusion in horses.
Monroe, VL; Papich, MG; Roberts, MC; Sellon, DC, 2001
)
0.31
" The dosing intervals suggested by our study are 2 to 3 h for morphine in both rats and mice, 1 to 2 h for butorphanol in both rats and mice; and 6 to 8 h in rats and 3 to 5 h in mice for buprenorphine."( The magnitude and duration of the analgesic effect of morphine, butorphanol, and buprenorphine in rats and mice.
Danneman, PJ; Gades, NM; Tolley, EA; Wixson, SK, 2000
)
0.31
" These data suggest that these kappa-agonists may be safely administered in the presence of cocaine but do not produce significant attenuation of cocaine's direct effects or self-administration under these acute dosing conditions."( Enadoline and butorphanol: evaluation of kappa-agonists on cocaine pharmacodynamics and cocaine self-administration in humans.
Bigelow, GE; Geter-Douglas, B; Strain, EC; Walsh, SL, 2001
)
0.31
" By reducing the dosage of Medetomidine, reduced cardio-respiratory side-effects are to be expected."( [Medetomidine-butorphanol combination anesthesia in the dog].
Boschung, H; Busato, A; Güller, K; Lang, MJ, 2001
)
0.31
" Explanations for these results include: (a) the analgesics were effective in relieving pain but had pharmacological side effects that altered the measured parameters, making it difficult to determine recovery; (b) the level of pain experienced did not notably affect recovery; (c) the analgesics, at the doses and/or dosing schedules used, were not effective in the relief of pain, thereby causing both groups of animals to recover at the same rate; and (d) the analgesics interfered with recovery."( Recovery of male rats from major abdominal surgery after treatment with various analgesics.
Azar, T; Lawson, D; Sharp, J; Zammit, T, 2003
)
0.32
"Results obtained by use of a thermal stimulus indicated that the duration of antinociceptive action of butorphanol was 90 minutes and there was no dose-response relationship in cats."( Use of thermal threshold response to evaluate the antinociceptive effects of butorphanol in cats.
Lascelles, BD; Robertson, SA, 2004
)
0.32
" Its transnasal dosage form, which may be self-administered when the use of an opioid analgesic is appropriate, was previously shown to provide rapid relief of migraine pain."( Comparison of butorphanol nasal spray and fiorinal with codeine in the treatment of migraine.
Davidson, WJ; Diamond, S; Gawel, MJ; Goldstein, J; Reich, L; Sussman, NM; Winner, P,
)
0.13
" An initial hand-injection of detomidine hydrochloride and butorphanol tartrate at a ratio of 1:1 on a microg:microg basis was administered intramuscularly, with a dosage range of 50-70 mg (12."( Standing sedation in African elephants (Loxodonta africana) using detomidine-butorphanol combinations.
Fontenot, DK; Miller, MA; Neiffer, DL; Pye, GW; Robbins, PK; Stetter, M; Weber, M, 2005
)
0.33
" The dose-response curves of butorphanol were studied using selective MOR and KOR antagonists."( Effects of butorphanol on morphine-induced itch and analgesia in primates.
Ko, MC; Lee, H; Naughton, NN; Woods, JH, 2007
)
0.34
"In RTHs and GHOs, butorphanol was rapidly absorbed and distributed via all routes of administration; the drug's rapid terminal half-life indicated that published dosing intervals for birds may be inadequate in RTHs and GHOs."( Pharmacokinetics of butorphanol tartrate in red-tailed hawks (Buteo jamaicensis) and great horned owls (Bubo virginianus).
Craigmill, AL; Hawkins, MG; Kass, PH; Riggs, SM; Stanley, SD; Taylor, IT, 2008
)
0.35
" Complete immobilization and excellent induction quality was achieved with a low volume dosage of BAM-2."( Butorphanol-azaperone-medetomidine for immobilization of captive white-tailed deer.
Howze, MB; Lance, WR; Miller, BF; Miller, KV; Osborn, DA; Warren, RJ, 2009
)
0.35
"Administration of a subanesthetic dosage of ketamine with xylazine and butorphanol may facilitate certain procedures, such as insertion of a dental float, in horses and enhance tolerance to pressure stimulation, but it may worsen responses to acute pain, such as that caused by a needle prick."( Evaluation of sedation and analgesia in standing horses after administration of xylazine, butorphanol, and subanesthetic doses of ketamine.
Contino, EK; Ferris, DJ; Kawcak, CE; Mama, KR; Wagner, AE, 2011
)
0.37
" Dose-response curves were generally quantal under the FR and graded under the FI schedules, but highly variable among subjects under the FI."( Drug discrimination in pigeons trained to discriminate among morphine, U50488, a combination of these drugs, and saline.
Li, M; McMillan, DE; Wessinger, WD, 2011
)
0.37
" We conclude that the feeding produced by BT is sensitive to dose and dosing paradigm."( Effects of butorphanol on feeding and neuropeptide Y in the rat.
Billington, CJ; Grace, MK; Kim, EM; Kotz, CM; Kuskowski, MA; Levine, AS; Mitra, A, 2012
)
0.38
" However, despite studies reporting the analgesic properties of butorphanol in psittacine birds, dosing intervals have not been established for any psittacine species."( Pharmacokinetics of butorphanol after intravenous, intramuscular, and oral administration in Hispaniolan Amazon parrots (Amazona ventralis).
Barker, SA; Flammer, K; Guzman, DS; Paul-Murphy, JR; Tully, TN, 2011
)
0.37
" After an interval of ≥ 1 week, the MAC reduction experiment was repeated with an increased butorphanol dosage (4 mg/kg)."( Effects of butorphanol on the minimum anesthetic concentration for sevoflurane in guineafowl (Numida meleagris).
Brosnan, RJ; Coelho, CM; Denicol, AC; Escobar, A; Flôres, FN; Thiesen, R; Valadão, CA, 2012
)
0.38
" Increasing the butorphanol dosage decreased the MAC for sevoflurane, but the effect was small and of short duration for dosages up to 4 mg/kg."( Effects of butorphanol on the minimum anesthetic concentration for sevoflurane in guineafowl (Numida meleagris).
Brosnan, RJ; Coelho, CM; Denicol, AC; Escobar, A; Flôres, FN; Thiesen, R; Valadão, CA, 2012
)
0.38
" The total Telazol dosage was also significantly different between young lemurs (33 +/- 15 mg/kg) and mature lemurs (18 +/- 9 mg/kg)."( Field anesthesia of wild ring-tailed lemurs (Lemur catta) using tiletamine-zolazepam, medetomidine, and butorphanol.
Cuozzo, FP; Larsen, RS; Moresco, A; Sauther, ML, 2011
)
0.37
" However, because of high first-pass metabolism butorphanol is not available in market as oral dosage form."( Development and evaluation of oral osmotic pump of butorphanol tartrate.
Misra, A; Raichandani, Y; Shah, B, 2014
)
0.4
" En résumé, l'application de S-kétamine à un dosage correspondant à 60% de celui de la kétamine racémique produit une anesthésie similaire."( Racemic ketamine in comparison to S-ketamine in combination with azaperone and butorphanol for castration of pigs.
Bettschart-Wolfensberger, R; Flaherty, D; Hässig, M; Ringer, SK; Stauffer, S, 2013
)
0.39
" Secondly, we examined how different dosage and optimum injection timing of ATI affected mice recovery from anesthesia."( Anesthetic effects of a three-drugs mixture--comparison of administrative routes and antagonistic effects of atipamezole in mice.
Kirihara, Y; Kobayashi, Y; Kurosaki, K; Saito, Y; Takechi, M; Takeuchi, T, 2015
)
0.42
" Sustained-release (SR) formulations of analgesics maintain plasma levels that should be sufficient to provide sustained analgesia yet require less frequent dosing and thus less handling of and stress to the animals."( Pharmacokinetics of sustained-release analgesics in mice.
Dorsey, K; Gustafson, DL; Hansen, RJ; Kang, S; Kendall, LV; Lunghofer, PJ, 2014
)
0.4
" During anaesthesia, minor veterinary procedures such a blood collection, intubation, vaccination and collaring could safely be performed with no additional dosing required."( Evaluation of BAM (butorphanol-azaperone-medetomidine) in captive African lion (Panthera leo) immobilization.
Andrianov, V; Laubscher, L; Orro, T; Pfitzer, S; Raath, JP; Semjonov, A; Venter, D, 2017
)
0.46
" A dose-response trial was conducted whereby 10, 30, and 50 mg/kg alfaxalone was administered subcutaneously (SC) to 10 Bengalese finches ( Lonchura domestica) in a randomized complete crossover study design."( ALFAXALONE ANESTHESIA IN THE BENGALESE FINCH ( LONCHURA DOMESTICA).
Bertelsen, MF; Nielsen, JB; Perrin, KL; Thomsen, AF, 2017
)
0.46
" Subsequently a dosage algorithm for the main trial was developed."( [Evaluation of a field-suitable injection anesthesia protocol for the castration of 8 to 14 days old piglets].
Bettschart-Wolfensberger, R; Nussbaumer, I; Rigamonti, S; Schwarz, A, 2018
)
0.48
" Les résultats ont servi de base pour l’algorithme de dosage de l’essai principal."( [Evaluation of a field-suitable injection anesthesia protocol for the castration of 8 to 14 days old piglets].
Bettschart-Wolfensberger, R; Nussbaumer, I; Rigamonti, S; Schwarz, A, 2018
)
0.48
" Response to noxious stimuli was absent in 2 of the rabbits given dexmedetomidine only, 4 of those given alfaxalone with dexmedetomidine, and all 6 of the animals dosed with alfaxalone, butorphanol, and dexmedetomidine; this last group displayed the longest absence of a toe-pinch response (57 ± 3 min)."( Intramuscular Administration of Alfaxalone Alone and in Combination for Sedation and Anesthesia of Rabbits (
Bradley, MP; Doerning, CM; Lester, PA; Nowland, MH, 2019
)
0.51
" The intravenous pharmacokinetics of butorphanol dosed individually compared with co-administration with detomidine had approximately a twofold larger clearance (646 ± 137 vs."( The intravenous pharmacokinetics of butorphanol and detomidine dosed in combination compared with individual dose administrations to exercised horses.
Bright, J; Hannan, C; Hillyer, L; Hincks, PR; Machnik, M; Paine, SW; Pearce, CM; Scarth, JP, 2020
)
0.56
"5 μg/kg butorphanol with propofol can be the optimal dosage for patients undergoing gastroscopy and colonoscopy."( Anesthetic effect of different doses of butorphanol in patients undergoing gastroscopy and colonoscopy.
Feng, Y; Li, J; Lv, S; Sun, D; Sun, Z; Yang, L, 2021
)
0.62
"Compared to dexmedetomidine alone, a small dose of butorphanol infusion (1 mg) as an adjunct treatment to dexmedetomidine during DISE can reduce the dosage of dexmedetomidine, shorten the time until sufficient sedation and enhance the performer satisfaction level."( Combination of Dexmedetomidine and Butorphanol Optimized Sedation in Drug-Induced Sleep Endoscopy: A Randomized, Double-Blind Trial.
Liao, WM; Liu, S; Zhang, XH, 2021
)
0.62
"To determine the effects of intravenous (IV) premedication with acepromazine, butorphanol or their combination, on the propofol anesthetic induction dosage in dogs."( Effects of intravenous acepromazine and butorphanol on propofol dosage for induction of anesthesia in healthy Beagle dogs.
Dantino, SC; Kleine, SA; Seddighi, R; Smith, CK; Smith, SM; Zhu, X, 2022
)
0.72
"Although the largest decrease in propofol dosage required for intubation was after IV premedication with acepromazine and butorphanol, hypotension and apnea still occurred."( Effects of intravenous acepromazine and butorphanol on propofol dosage for induction of anesthesia in healthy Beagle dogs.
Dantino, SC; Kleine, SA; Seddighi, R; Smith, CK; Smith, SM; Zhu, X, 2022
)
0.72
"The purpose of this study was to improve butorphanol dosing in dogs."( Dosing protocols to increase the efficacy of butorphanol in dogs.
Gray, M; KuKanich, B; KuKanich, K; Lai, P; Springfield, D, 2022
)
0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
opioid analgesicA narcotic or opioid substance, synthetic or semisynthetic agent producing profound analgesia, drowsiness, and changes in mood.
mu-opioid receptor agonistA compound that exhibits agonist activity at the mu-opioid receptor.
kappa-opioid receptor agonistA compound that exhibits agonist activity at the kappa-opioid receptor.
antitussiveAn agent that suppresses cough. Antitussives have a central or a peripheral action on the cough reflex, or a combination of both. Compare with expectorants, which are considered to increase the volume of secretions in the respiratory tract, so facilitating their removal by ciliary action and coughing, and mucolytics, which decrease the viscosity of mucus, facilitating its removal by ciliary action and expectoration.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
morphinane alkaloidAn isoquinoline alkaloid based on a morphinan skeleton and its substituted derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (7)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Bile salt export pumpHomo sapiens (human)IC50 (µMol)134.00000.11007.190310.0000AID1443980; AID1473738
Mu-type opioid receptorHomo sapiens (human)IC50 (µMol)0.01400.00010.813310.0000AID410730
Mu-type opioid receptorHomo sapiens (human)Ki0.00020.00000.419710.0000AID362196; AID410718; AID596551
Delta-type opioid receptorHomo sapiens (human)Ki0.01200.00000.59789.9300AID362197; AID410719; AID596638
Kappa-type opioid receptorHomo sapiens (human)Ki0.00020.00000.362410.0000AID362198; AID410720; AID596552
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Kappa-type opioid receptorHomo sapiens (human)EC50 (µMol)0.00290.00000.22448.9900AID410731
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (90)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMu-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
sensory perceptionMu-type opioid receptorHomo sapiens (human)
negative regulation of cell population proliferationMu-type opioid receptorHomo sapiens (human)
sensory perception of painMu-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
behavioral response to ethanolMu-type opioid receptorHomo sapiens (human)
positive regulation of neurogenesisMu-type opioid receptorHomo sapiens (human)
negative regulation of Wnt protein secretionMu-type opioid receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeMu-type opioid receptorHomo sapiens (human)
calcium ion transmembrane transportMu-type opioid receptorHomo sapiens (human)
cellular response to morphineMu-type opioid receptorHomo sapiens (human)
regulation of cellular response to stressMu-type opioid receptorHomo sapiens (human)
regulation of NMDA receptor activityMu-type opioid receptorHomo sapiens (human)
neuropeptide signaling pathwayMu-type opioid receptorHomo sapiens (human)
immune responseDelta-type opioid receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerDelta-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
adult locomotory behaviorDelta-type opioid receptorHomo sapiens (human)
negative regulation of gene expressionDelta-type opioid receptorHomo sapiens (human)
negative regulation of protein-containing complex assemblyDelta-type opioid receptorHomo sapiens (human)
positive regulation of CREB transcription factor activityDelta-type opioid receptorHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationDelta-type opioid receptorHomo sapiens (human)
response to nicotineDelta-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
eating behaviorDelta-type opioid receptorHomo sapiens (human)
regulation of mitochondrial membrane potentialDelta-type opioid receptorHomo sapiens (human)
regulation of calcium ion transportDelta-type opioid receptorHomo sapiens (human)
cellular response to growth factor stimulusDelta-type opioid receptorHomo sapiens (human)
cellular response to hypoxiaDelta-type opioid receptorHomo sapiens (human)
cellular response to toxic substanceDelta-type opioid receptorHomo sapiens (human)
neuropeptide signaling pathwayDelta-type opioid receptorHomo sapiens (human)
immune responseKappa-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
chemical synaptic transmissionKappa-type opioid receptorHomo sapiens (human)
sensory perceptionKappa-type opioid receptorHomo sapiens (human)
locomotory behaviorKappa-type opioid receptorHomo sapiens (human)
sensory perception of painKappa-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting opioid receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
response to insulinKappa-type opioid receptorHomo sapiens (human)
positive regulation of dopamine secretionKappa-type opioid receptorHomo sapiens (human)
negative regulation of luteinizing hormone secretionKappa-type opioid receptorHomo sapiens (human)
response to nicotineKappa-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
maternal behaviorKappa-type opioid receptorHomo sapiens (human)
eating behaviorKappa-type opioid receptorHomo sapiens (human)
response to estrogenKappa-type opioid receptorHomo sapiens (human)
estrous cycleKappa-type opioid receptorHomo sapiens (human)
response to ethanolKappa-type opioid receptorHomo sapiens (human)
regulation of saliva secretionKappa-type opioid receptorHomo sapiens (human)
behavioral response to cocaineKappa-type opioid receptorHomo sapiens (human)
sensory perception of temperature stimulusKappa-type opioid receptorHomo sapiens (human)
defense response to virusKappa-type opioid receptorHomo sapiens (human)
cellular response to lipopolysaccharideKappa-type opioid receptorHomo sapiens (human)
cellular response to glucose stimulusKappa-type opioid receptorHomo sapiens (human)
positive regulation of p38MAPK cascadeKappa-type opioid receptorHomo sapiens (human)
positive regulation of potassium ion transmembrane transportKappa-type opioid receptorHomo sapiens (human)
response to acrylamideKappa-type opioid receptorHomo sapiens (human)
positive regulation of eating behaviorKappa-type opioid receptorHomo sapiens (human)
conditioned place preferenceKappa-type opioid receptorHomo sapiens (human)
neuropeptide signaling pathwayKappa-type opioid receptorHomo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (35)

Processvia Protein(s)Taxonomy
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
G-protein alpha-subunit bindingMu-type opioid receptorHomo sapiens (human)
G protein-coupled receptor activityMu-type opioid receptorHomo sapiens (human)
beta-endorphin receptor activityMu-type opioid receptorHomo sapiens (human)
voltage-gated calcium channel activityMu-type opioid receptorHomo sapiens (human)
protein bindingMu-type opioid receptorHomo sapiens (human)
morphine receptor activityMu-type opioid receptorHomo sapiens (human)
G-protein beta-subunit bindingMu-type opioid receptorHomo sapiens (human)
neuropeptide bindingMu-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor activityDelta-type opioid receptorHomo sapiens (human)
protein bindingDelta-type opioid receptorHomo sapiens (human)
receptor serine/threonine kinase bindingDelta-type opioid receptorHomo sapiens (human)
G protein-coupled enkephalin receptor activityDelta-type opioid receptorHomo sapiens (human)
neuropeptide bindingDelta-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor activityKappa-type opioid receptorHomo sapiens (human)
protein bindingKappa-type opioid receptorHomo sapiens (human)
receptor serine/threonine kinase bindingKappa-type opioid receptorHomo sapiens (human)
dynorphin receptor activityKappa-type opioid receptorHomo sapiens (human)
neuropeptide bindingKappa-type opioid receptorHomo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (36)

Processvia Protein(s)Taxonomy
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
endosomeMu-type opioid receptorHomo sapiens (human)
endoplasmic reticulumMu-type opioid receptorHomo sapiens (human)
Golgi apparatusMu-type opioid receptorHomo sapiens (human)
plasma membraneMu-type opioid receptorHomo sapiens (human)
axonMu-type opioid receptorHomo sapiens (human)
dendriteMu-type opioid receptorHomo sapiens (human)
perikaryonMu-type opioid receptorHomo sapiens (human)
synapseMu-type opioid receptorHomo sapiens (human)
plasma membraneMu-type opioid receptorHomo sapiens (human)
neuron projectionMu-type opioid receptorHomo sapiens (human)
plasma membraneDelta-type opioid receptorHomo sapiens (human)
synaptic vesicle membraneDelta-type opioid receptorHomo sapiens (human)
dendrite membraneDelta-type opioid receptorHomo sapiens (human)
presynaptic membraneDelta-type opioid receptorHomo sapiens (human)
axon terminusDelta-type opioid receptorHomo sapiens (human)
spine apparatusDelta-type opioid receptorHomo sapiens (human)
postsynaptic density membraneDelta-type opioid receptorHomo sapiens (human)
neuronal dense core vesicleDelta-type opioid receptorHomo sapiens (human)
plasma membraneDelta-type opioid receptorHomo sapiens (human)
neuron projectionDelta-type opioid receptorHomo sapiens (human)
nucleoplasmKappa-type opioid receptorHomo sapiens (human)
mitochondrionKappa-type opioid receptorHomo sapiens (human)
cytosolKappa-type opioid receptorHomo sapiens (human)
plasma membraneKappa-type opioid receptorHomo sapiens (human)
membraneKappa-type opioid receptorHomo sapiens (human)
sarcoplasmic reticulumKappa-type opioid receptorHomo sapiens (human)
T-tubuleKappa-type opioid receptorHomo sapiens (human)
dendriteKappa-type opioid receptorHomo sapiens (human)
synaptic vesicle membraneKappa-type opioid receptorHomo sapiens (human)
presynaptic membraneKappa-type opioid receptorHomo sapiens (human)
perikaryonKappa-type opioid receptorHomo sapiens (human)
axon terminusKappa-type opioid receptorHomo sapiens (human)
postsynaptic membraneKappa-type opioid receptorHomo sapiens (human)
plasma membraneKappa-type opioid receptorHomo sapiens (human)
neuron projectionKappa-type opioid receptorHomo sapiens (human)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (95)

Assay IDTitleYearJournalArticle
AID1443980Inhibition of human BSEP expressed in fall armyworm sf9 cell plasma membrane vesicles assessed as reduction in vesicle-associated [3H]-taurocholate transport preincubated for 10 mins prior to ATP addition measured after 15 mins in presence of [3H]-tauroch2010Toxicological sciences : an official journal of the Society of Toxicology, Dec, Volume: 118, Issue:2
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
AID128027Compound was tested for analgesic activity by writhing assay in mouse after subcutaneous administration1981Journal of medicinal chemistry, Jun, Volume: 24, Issue:6
Analgesic narcotic antagonists. 6. 7 beta, 8 beta-Methano- and 7 beta, 8 beta-epoxydihydrocodeinone.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID7783Unbound fraction (plasma)2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID230878Ratio of agonist potency to antagonist potency was determined1980Journal of medicinal chemistry, Dec, Volume: 23, Issue:12
Analgesic narcotic antagonists. 4. 7-Methyl-N-(cycloalkylmethyl)-3-hydroxymorphinan-6-ones and -isomorphinan-6-ones.
AID678722Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID8002Observed volume of distribution2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID410721Ratio of Ki for human mu opioid receptor to Ki for human kappa opioid receptor expressed in CHO cells2009Bioorganic & medicinal chemistry letters, Jan-01, Volume: 19, Issue:1
Syntheses and opioid receptor binding properties of carboxamido-substituted opioids.
AID410719Displacement of [3H]Naltrindole form human delta opioid receptor expressed in CHO cells2009Bioorganic & medicinal chemistry letters, Jan-01, Volume: 19, Issue:1
Syntheses and opioid receptor binding properties of carboxamido-substituted opioids.
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID596638Displacement of [3H]naltrindole from human delta-opioid receptor expressed in CHO cells after 3 hrs by scintillation counting2011Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9
Synthesis and binding affinity of novel mono- and bivalent morphinan ligands for κ, μ, and δ opioid receptors.
AID362198Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cell membrane2008Bioorganic & medicinal chemistry letters, Aug-15, Volume: 18, Issue:16
Synthesis and pharmacological evaluation of hydrophobic esters and ethers of butorphanol at opioid receptors.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1148433Narcotic antagonist activity in sc dosed mouse assessed as reversal of oxymorphone-induced straub tail response administered 10 mins before oxymorphone challenge1978Journal of medicinal chemistry, May, Volume: 21, Issue:5
Analgesics and narcotic antagonists in the benzomorphan and 8-oxamorphinan series. 5.
AID678717Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID678715Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID362196Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membrane2008Bioorganic & medicinal chemistry letters, Aug-15, Volume: 18, Issue:16
Synthesis and pharmacological evaluation of hydrophobic esters and ethers of butorphanol at opioid receptors.
AID781328pKa (acid-base dissociation constant) as determined by Luan ref: Pharm. Res. 20052014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID178687Compound was tested for narcotic antagonist activity determined using an intraperitoneal ED80 of morphine in rat tail-flick assay1981Journal of medicinal chemistry, Jun, Volume: 24, Issue:6
Analgesic narcotic antagonists. 6. 7 beta, 8 beta-Methano- and 7 beta, 8 beta-epoxydihydrocodeinone.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1135279Narcotic antagonist activity in sc dosed rat assessed as reversal of oxymorphone-induced loss of righting reflex1977Journal of medicinal chemistry, May, Volume: 20, Issue:5
5-allyl-9-oxobenzomorphans. 3. Potent narcotic antagonists and analgesics-antagonists in the series of substituted 2',9beta-dihydroxy-6,7-benzomorphans.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID596552Displacement of [3H]U69563 from human kappa-opioid receptor expressed in CHO cells after 60 mins by scintillation counting2011Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9
Synthesis and binding affinity of novel mono- and bivalent morphinan ligands for κ, μ, and δ opioid receptors.
AID230879Ratio of agonist to that of antagonist activity1980Journal of medicinal chemistry, Feb, Volume: 23, Issue:2
Analgesic narcotic antagonists. 2. 8-Alkymorphinan-6-ones.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID362200Selectivity ratio of Ki for human mu opioid receptor to Ki for human delta opioid receptor2008Bioorganic & medicinal chemistry letters, Aug-15, Volume: 18, Issue:16
Synthesis and pharmacological evaluation of hydrophobic esters and ethers of butorphanol at opioid receptors.
AID178684Narcotic antagonist activity in heat stimulus rat tail flick assay after subcutaneous administration1981Journal of medicinal chemistry, Dec, Volume: 24, Issue:12
Analgesic narcotic antagonists. 8. 7 alpha-Alkyl-4,5 alpha-epoxymorphinan-6-ones.
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID410718Displacement of [3H]DAMGO form human mu opioid receptor expressed in CHO cells2009Bioorganic & medicinal chemistry letters, Jan-01, Volume: 19, Issue:1
Syntheses and opioid receptor binding properties of carboxamido-substituted opioids.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID410730Activity at human cloned mu opioid receptor expressed in CHO cells assessed as inhibition of DAMGO-induced [35S]GTPgammaS binding2009Bioorganic & medicinal chemistry letters, Jan-01, Volume: 19, Issue:1
Syntheses and opioid receptor binding properties of carboxamido-substituted opioids.
AID178158Antagonist activity in rat tail flick assay by intraperitoneal administration1980Journal of medicinal chemistry, Dec, Volume: 23, Issue:12
Analgesic narcotic antagonists. 4. 7-Methyl-N-(cycloalkylmethyl)-3-hydroxymorphinan-6-ones and -isomorphinan-6-ones.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID178685Inhibition of morphine analgesia in modified rat tail flick test.1981Journal of medicinal chemistry, Dec, Volume: 24, Issue:12
Analgesic narcotic antagonists. 9. 6-Methylene-8 beta-alkyl-N-(cycloalkylmethyl)-3-hydroxy- or -methoxymorphinans.
AID1135278Narcotic antagonist activity in sc dosed rat assessed as reversal of morphine-induced analgesia by tail-flick test1977Journal of medicinal chemistry, May, Volume: 20, Issue:5
5-allyl-9-oxobenzomorphans. 3. Potent narcotic antagonists and analgesics-antagonists in the series of substituted 2',9beta-dihydroxy-6,7-benzomorphans.
AID410720Displacement of [3H]U69593 form human kappa opioid receptor expressed in CHO cells2009Bioorganic & medicinal chemistry letters, Jan-01, Volume: 19, Issue:1
Syntheses and opioid receptor binding properties of carboxamido-substituted opioids.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID539464Solubility of the compound in 0.1 M phosphate buffer at 600 uM at pH 7.4 after 24 hrs by LC/MS/MS analysis2010Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
AID678716Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1135280Analgesic activity in sc dosed rat assessed as reduction in phenylquinone-induced writhing administered 15 mins prior to phenylquinone-challenge measured up to 10 mins1977Journal of medicinal chemistry, May, Volume: 20, Issue:5
5-allyl-9-oxobenzomorphans. 3. Potent narcotic antagonists and analgesics-antagonists in the series of substituted 2',9beta-dihydroxy-6,7-benzomorphans.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1148436Antagonist activity in rat assessed as morphine-induced analgesia by hot plate tail flick test1978Journal of medicinal chemistry, May, Volume: 21, Issue:5
Analgesics and narcotic antagonists in the benzomorphan and 8-oxamorphinan series. 5.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID128023Compound was tested for analgesia in mouse writhing assay by subcutaneous administration1980Journal of medicinal chemistry, Dec, Volume: 23, Issue:12
Analgesic narcotic antagonists. 4. 7-Methyl-N-(cycloalkylmethyl)-3-hydroxymorphinan-6-ones and -isomorphinan-6-ones.
AID596649Selectivity ratio of Ki for human kappa opioid receptor over Ki for human mu opioid receptor2011Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9
Synthesis and binding affinity of novel mono- and bivalent morphinan ligands for κ, μ, and δ opioid receptors.
AID132133The effective dose was measured by using mouse writhing assay after the compound administered subcutaneously.1980Journal of medicinal chemistry, Feb, Volume: 23, Issue:2
Analgesic narcotic antagonists. 2. 8-Alkymorphinan-6-ones.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID678714Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID128019Inhibition of acetic acid induced mouse writhing assay following s.c. administration.1981Journal of medicinal chemistry, Dec, Volume: 24, Issue:12
Analgesic narcotic antagonists. 9. 6-Methylene-8 beta-alkyl-N-(cycloalkylmethyl)-3-hydroxy- or -methoxymorphinans.
AID596650Selectivity ratio of Ki for human kappa opioid receptor over Ki for human delta opioid receptor2011Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9
Synthesis and binding affinity of novel mono- and bivalent morphinan ligands for κ, μ, and δ opioid receptors.
AID178879Narcotic antagonist activity against an ED80 of morphine in the modified rat tail-flick assay1981Journal of medicinal chemistry, Jun, Volume: 24, Issue:6
Analgesic narcotic antagonists. 5. 7,7-Dimethyldihydrocodeinones and 7,7-dimethyldihydromorphinones.
AID1148434Analgesic activity in sc dosed rat assessed as phenylquinone-induced writhing measured for 10 mins1978Journal of medicinal chemistry, May, Volume: 21, Issue:5
Analgesics and narcotic antagonists in the benzomorphan and 8-oxamorphinan series. 5.
AID180011The effective dose was measured by using rat tail flick assay after the compound administered intraperitoneally.1980Journal of medicinal chemistry, Feb, Volume: 23, Issue:2
Analgesic narcotic antagonists. 2. 8-Alkymorphinan-6-ones.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1148432Analgesic activity in sc dosed mouse assessed as phenylquinone-induced writhing measured for 10 mins1978Journal of medicinal chemistry, May, Volume: 21, Issue:5
Analgesics and narcotic antagonists in the benzomorphan and 8-oxamorphinan series. 5.
AID1135289Narcotic antagonist activity in sc dosed mouse assessed as inhibition of oxymorphone-induced straub tail response administered 10 mins post oxymorphone-challenge1977Journal of medicinal chemistry, May, Volume: 20, Issue:5
5-allyl-9-oxobenzomorphans. 3. Potent narcotic antagonists and analgesics-antagonists in the series of substituted 2',9beta-dihydroxy-6,7-benzomorphans.
AID678721Metabolic stability in human liver microsomes assessed as GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID410733Activity at human cloned kappa opioid receptor expressed in CHO cells assessed as inhibition of U50488-induced [35S]GTPgammaS binding2009Bioorganic & medicinal chemistry letters, Jan-01, Volume: 19, Issue:1
Syntheses and opioid receptor binding properties of carboxamido-substituted opioids.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID410729Activity at human cloned mu opioid receptor expressed in CHO cells by [35S]GTPgammaS binding assay relative to basal GTPgammaS binding2009Bioorganic & medicinal chemistry letters, Jan-01, Volume: 19, Issue:1
Syntheses and opioid receptor binding properties of carboxamido-substituted opioids.
AID26362Ionization constant (pKa)2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID362197Displacement of [3H]Naltindole from human delta opioid receptor expressed in CHO cell membrane2008Bioorganic & medicinal chemistry letters, Aug-15, Volume: 18, Issue:16
Synthesis and pharmacological evaluation of hydrophobic esters and ethers of butorphanol at opioid receptors.
AID362201Selectivity ratio of Ki for human mu opioid receptor to Ki for human kappa opioid receptor2008Bioorganic & medicinal chemistry letters, Aug-15, Volume: 18, Issue:16
Synthesis and pharmacological evaluation of hydrophobic esters and ethers of butorphanol at opioid receptors.
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID596551Displacement of [3H]DAMGO from human mu-opioid receptor expressed in CHO cells after 60 mins by scintillation counting2011Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9
Synthesis and binding affinity of novel mono- and bivalent morphinan ligands for κ, μ, and δ opioid receptors.
AID410732Activity at human cloned kappa opioid receptor expressed in CHO cells by [35S]GTPgammaS binding assay relative to basal GTPgammaS binding2009Bioorganic & medicinal chemistry letters, Jan-01, Volume: 19, Issue:1
Syntheses and opioid receptor binding properties of carboxamido-substituted opioids.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID678712Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1148435Narcotic antagonist activity in sc dosed mouse assessed as reversal of oxymorphone-induced narcosis1978Journal of medicinal chemistry, May, Volume: 21, Issue:5
Analgesics and narcotic antagonists in the benzomorphan and 8-oxamorphinan series. 5.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID131018Analgesic agonist activity in acetic acid induced mouse writhing assay, subcutaneous administration1981Journal of medicinal chemistry, Jun, Volume: 24, Issue:6
Analgesic narcotic antagonists. 5. 7,7-Dimethyldihydrocodeinones and 7,7-dimethyldihydromorphinones.
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID410722Ratio of Ki for human delta opioid receptor to Ki for human kappa opioid receptor expressed in CHO cells2009Bioorganic & medicinal chemistry letters, Jan-01, Volume: 19, Issue:1
Syntheses and opioid receptor binding properties of carboxamido-substituted opioids.
AID362199Selectivity ratio of Ki for human kappa opioid receptor to Ki for human delta opioid receptor2008Bioorganic & medicinal chemistry letters, Aug-15, Volume: 18, Issue:16
Synthesis and pharmacological evaluation of hydrophobic esters and ethers of butorphanol at opioid receptors.
AID128214Narcotic agonistic activity in acetic acid mouse writhing assay after subcutaneous administration of the drug1981Journal of medicinal chemistry, Dec, Volume: 24, Issue:12
Analgesic narcotic antagonists. 8. 7 alpha-Alkyl-4,5 alpha-epoxymorphinan-6-ones.
AID1135281Analgesic activity in sc dosed mouse assessed as reduction in phenylquinone-induced writhing administered 15 mins prior to phenylquinone-challenge measured up to 10 mins1977Journal of medicinal chemistry, May, Volume: 20, Issue:5
5-allyl-9-oxobenzomorphans. 3. Potent narcotic antagonists and analgesics-antagonists in the series of substituted 2',9beta-dihydroxy-6,7-benzomorphans.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID678713Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID410731Activity at human cloned kappa opioid receptor expressed in CHO cells by [35S]GTPgammaS binding assay2009Bioorganic & medicinal chemistry letters, Jan-01, Volume: 19, Issue:1
Syntheses and opioid receptor binding properties of carboxamido-substituted opioids.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1346364Human mu receptor (Opioid receptors)2008Bioorganic & medicinal chemistry letters, Aug-15, Volume: 18, Issue:16
Synthesis and pharmacological evaluation of hydrophobic esters and ethers of butorphanol at opioid receptors.
AID1346329Human kappa receptor (Opioid receptors)2008Bioorganic & medicinal chemistry letters, Aug-15, Volume: 18, Issue:16
Synthesis and pharmacological evaluation of hydrophobic esters and ethers of butorphanol at opioid receptors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,132)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990221 (19.52)18.7374
1990's266 (23.50)18.2507
2000's243 (21.47)29.6817
2010's288 (25.44)24.3611
2020's114 (10.07)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials395 (32.04%)5.53%
Reviews41 (3.33%)6.00%
Case Studies43 (3.49%)4.05%
Observational0 (0.00%)0.25%
Other754 (61.15%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (14)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Hydromorphone for ICU-analgesia in Patients With Non-mechanical Ventilation: A Dose-exploration and Effectiveness Study [NCT04436224]Phase 4530 participants (Anticipated)Interventional2020-09-04Recruiting
Efficacy and Safety of Butorphanol Tartrate Injection for the Patients With Mechanical Ventilation:a Randomized and Controlled Trial [NCT05201560]40 participants (Anticipated)Interventional2022-01-31Not yet recruiting
Using Preoperative Anxiety Score to Determine the Total Dose of Butorphanol for Sedation in Patients Undergoing Lower Limb Orthopedic Procedures: A Randomized, Double-blind, Placebo-controlled Study [NCT03810391]Phase 2126 participants (Actual)Interventional2017-12-01Completed
The Analgesic Effect of Butorphanol After Cesarean Section [NCT04490980]100 participants (Anticipated)Interventional2020-08-01Not yet recruiting
Comparison of Analgesic Efficacy of Fentanyl, Sufentanil and Butorphanol After Remifentanil Anesthesia in Gynecological Laparoscopic Surgeries [NCT00738192]Phase 4150 participants (Actual)Interventional2008-07-31Completed
Propofol-butorphanol Combined Anesthesia During Uterine Curettage on Abortion [NCT00795314]Phase 4150 participants (Actual)Interventional2008-11-30Completed
Comparison of Analgesic Effect and Prognosis of Butorphanol and Fentanyl in Patients With Mechanical Ventilation: a Prospective, Randomized, Multicenter Clinical Study [NCT04315935]Phase 4355 participants (Anticipated)Interventional2019-12-15Recruiting
Effectiveness of Butorphanol in Alleviating Postoperative Visceral Pain Following Microwave Ablation for Hepatic Tumor: A Multicentral, Randomized, Placebo-Controlled Trial [NCT06031129]300 participants (Actual)Interventional2023-03-01Completed
Butorphanol and Tramadol for Morphine PCA Pain Management After Total Hysterectomy [NCT00510666]Phase 4841 participants (Actual)Interventional2007-01-31Completed
Effect of Different Sedation and Analgesia Strategies on Patients With Mechanical Ventilation [NCT05024799]Phase 4300 participants (Anticipated)Interventional2022-01-31Not yet recruiting
Effect of Butorphanol Combined With Flurbiprofen Axetil on Preventing Postoperative Hyperalgesia Induced by Remifentanil in Patients Undergoing Lower Abdomimal Surgery [NCT02043366]180 participants (Actual)Interventional2014-02-28Completed
Effect of Butorphanol on Colonoscopy for Patients With Postoperative Visceral Pain [NCT04477733]Phase 4203 participants (Actual)Interventional2020-08-14Completed
Using Pre-operative Anxiety Score to Determine the Precise Dose of Butorphanol in Patients Undergoing Orthopedic Procedures: A Double-blinded Randomized Trial [NCT03429179]Phase 2155 participants (Actual)Interventional2018-03-05Completed
Butorphanol Mitigate Emergence Agitation in Patients Undergoing Functional Endoscopic Sinus Surgery:a Randomized Control Double Blinded Clinical Trail [NCT03398759]700 participants (Anticipated)Interventional2018-02-01Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT02043366 (2) [back to overview]Mechanical Hyperalgesia Threshold on the Dominant Inner Forearm
NCT02043366 (2) [back to overview]Normalized Area of Hyperalgesia Around the Incision

Mechanical Hyperalgesia Threshold on the Dominant Inner Forearm

The mechanical hyperalgesia threshold was defined as the lowest force (g) necessary to bend a Von Frey filament, which was perceived to be painful by the patient and measured by Von Frey filament at 24 hours postoperatively (NCT02043366)
Timeframe: 24 hours after surgery

Interventiong (Mean)
Normal Saline60.57
Flurbiprofen AxetilⅠ78.29
Flurbiprofen AxetilⅡ68.50
Butorphanol79.7
Butorphanol-Flurbiprofen Axetil81.64
Sufentanil89.5

[back to top]

Normalized Area of Hyperalgesia Around the Incision

The skin around the incision is stimulated in steps of 5 mm at intervals of 1 s starting outside of the hyperalgesic area in the direction of the incision. The distance from the incision to the first point where a 'painful', 'sore' or 'sharper' feeling occurred is measured and noted. This measurement is repeated at predefined radial lines around the incision. To eliminate the variable length of incision, this length is subtracted from the longer diameter leaving four radial distances from the end and from the middle of the incision. The normalized area of hyperalgesia is calculated by summing up the areas of the remaining four triangles measured by and Von Frey filament. (NCT02043366)
Timeframe: 24 hours after surgery

Interventioncm^2 (Mean)
Normal Saline60.46
Flurbiprofen AxetilⅠ53.64
Flurbiprofen AxetilⅡ56.57
Butorphanol54.00
Butorphanol-Flurbiprofen Axetil52.5
Sufentanil49.89

[back to top]